NeuroCores, Inc.
201 Washington Street,
#2600. Boston,
MA 02108

Rett Syndrome

What is Rett Syndrome?

Rett syndrome is a rare genetic neurological disorder that occurs almost exclusively in girls, affecting nearly every aspect of a child’s life: their ability to speak, walk, eat, and even breathe easily. The hallmark of Rett syndrome is near-constant repetitive hand movements. Rett syndrome is usually recognized in children between 6 and 18 months as they begin to miss developmental milestones or lose abilities they had gained.

Rett syndrome is caused by mutations on the X chromosome on a gene called MECP2. There are more than 900 different mutations found on the MECP2 gene. Rett syndrome is not a degenerative disorder, as individuals can live to middle age or beyond. Rett syndrome occurs worldwide in 1 of every 10,000 female births and is even rarer in boys. Rett syndrome can present with a wide range of disability ranging from mild to severe. The course and severity of Rett syndrome is determined by the location, type and severity of the mutation and X-inactivation.

It is characterized by typical early growth and development, which is then followed by:

Loss of mobility or function in the hands
Distinctive hand movements
Slowed brain and head growth
Problems with walking, walking on the toes, or a wide-based gait
Cognitive problems
Digestive problems
Trouble performing motor functions, including speaking and controlling eye movements (apraxia)
Breathing difficulties while awake, including breath holding, hyperventilation, and swallowing air

The Product


KIT-13, a synthetic derivative of plasmalogen, has shown strong anti-inflammatory effects by inhibiting the nuclear accumulation of p65, suppressing the expression of IL-1β, and inducing phosphorylation of ERK

These findings suggest that KIT-13 may hold promise for treating Rett syndrome and other neurodegenerative diseases.

KIT – 13

Compared to natural plasmalogens that already have an anti-neuroinflammation effect, our synthetic derivative of plasmalogen has the following improvements:

Strong anti-neuroinflammation effect

BBB Penetration

High Brain Bioavailability

High Stability


We are committed to maintaining the highest standards of quality assurance and quality control throughout the development of our innovative plasmalogen derivative product development. Our rigorous protocols are designed to increase confidence in our findings and ensure the safety and efficacy of our therapeutic candidates.

Our Quality culture is defined by our commitment to integrity, transparency and compliance.

Integrity – Our commitment to integrity enables us to maintain a high level of trust with our partners, physicians and patients.

Transparency – We hold ourselves to the highest standard of openness and honesty with ourselves and with all the people who rely on us.

Compliance – We meet or exceed quality, industry, and global regulatory standards.